388 related articles for article (PubMed ID: 24169351)
1. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.
Jie HB; Gildener-Leapman N; Li J; Srivastava RM; Gibson SP; Whiteside TL; Ferris RL
Br J Cancer; 2013 Nov; 109(10):2629-35. PubMed ID: 24169351
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
[TBL] [Abstract][Full Text] [Related]
3. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
4. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
5. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
[TBL] [Abstract][Full Text] [Related]
6. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.
Mandapathil M; Lang S; Gorelik E; Whiteside TL
J Immunol Methods; 2009 Jul; 346(1-2):55-63. PubMed ID: 19450601
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.
Drennan S; Stafford ND; Greenman J; Green VL
Immunology; 2013 Nov; 140(3):335-43. PubMed ID: 23826668
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Jie HB; Schuler PJ; Lee SC; Srivastava RM; Argiris A; Ferrone S; Whiteside TL; Ferris RL
Cancer Res; 2015 Jun; 75(11):2200-10. PubMed ID: 25832655
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations.
Szeponik L; Ahlmanner F; Sundström P; Rodin W; Gustavsson B; Bexe Lindskog E; Wettergren Y; Quiding-Järbrink M
BMC Immunol; 2021 Aug; 22(1):58. PubMed ID: 34407765
[TBL] [Abstract][Full Text] [Related]
10. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
11. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
12. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression.
Sun W; Li WJ; Wu CY; Zhong H; Wen WP
J Exp Clin Cancer Res; 2014 Apr; 33(1):35. PubMed ID: 24761979
[TBL] [Abstract][Full Text] [Related]
13. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
14. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.
Schuler PJ; Harasymczuk M; Schilling B; Saze Z; Strauss L; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2013 Dec; 19(23):6585-96. PubMed ID: 24097865
[TBL] [Abstract][Full Text] [Related]
15. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
16. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes.
Parodi A; Battaglia F; Kalli F; Ferrera F; Conteduca G; Tardito S; Stringara S; Ivaldi F; Negrini S; Borgonovo G; Simonato A; Traverso P; Carmignani G; Fenoglio D; Filaci G
Cancer Immunol Immunother; 2013 May; 62(5):851-62. PubMed ID: 23359087
[TBL] [Abstract][Full Text] [Related]
17. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck.
Strauss L; Bergmann C; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Nov; 13(21):6301-11. PubMed ID: 17975141
[TBL] [Abstract][Full Text] [Related]
18. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis.
Wen YH; Lin HQ; Li H; Zhao Y; Lui VWY; Chen L; Wu XM; Sun W; Wen WP
Cancer Immunol Immunother; 2019 Feb; 68(2):221-232. PubMed ID: 30357458
[TBL] [Abstract][Full Text] [Related]
19. The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers.
Sun DS; Zhao MQ; Xia M; Li L; Jiang YH
Med Oncol; 2012 Jun; 29(2):707-13. PubMed ID: 21424865
[TBL] [Abstract][Full Text] [Related]
20. Circulating gluten-specific FOXP3
Cook L; Munier CML; Seddiki N; van Bockel D; Ontiveros N; Hardy MY; Gillies JK; Levings MK; Reid HH; Petersen J; Rossjohn J; Anderson RP; Zaunders JJ; Tye-Din JA; Kelleher AD
J Allergy Clin Immunol; 2017 Dec; 140(6):1592-1603.e8. PubMed ID: 28283419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
